United Therapeutics amends Ralinepag agreement with Pfizer's Arena, pays $525M to eliminate royalty obligations

United Therapeutics amended its exclusive license agreement with Arena Pharmaceuticals, a Pfizer subsidiary, related to Ralinepag, paying an upfront $525M to eliminate all royalty obligations under the agreement.

Detected & updated continuously · Source: Nebula